IDiyas

For the Inventor, By the Inventor

Copenhagen, Denmark

Janos Tibor Kodra

USPTO Granted Patents = 28 

 

 

Average Co-Inventor Count = 7.0

ph-index = 10

Forward Citations = 550(Granted Patents)


Location History:

  • Kobenhavn, DK (2005)
  • Koebenhavn O, DK (2014)
  • Bagsvaerd, DK (2014)
  • Cophenhagen, DK (2015)
  • Copenhagen, DK (2003 - 2020)
  • Koebenhavn Oe, DK (2015 - 2021)
  • Koebenhavn, DK (2019 - 2022)

Company Filing History:

goldMedal27 out of 1,777 
 
Novo Nordisk A/s
 patents
silverMedal1 out of 6 
 
Novo Nordick A/s
 patents

Years Active: 2003-2022

Loading Chart...
Loading Chart...
Loading Chart...
28 patents (USPTO):Explore Patents
1. 11471537 - Oligomer extended insulin-Fc conjugates (2022-10-18),
2. 10946074 - GLP-1 derivatives and uses thereof (2021-03-16),
3. 10822385 - EGF(A) analogues with fatty acid substituents (2020-11-03),
4. 10689429 - Double-acylated GLP-1 compounds (2020-06-23),
5. 10259856 - Protease stabilized acylated insulin analogues (2019-04-16),
6. 9708383 - Double-acylated GLP-1 derivatives (2017-07-18),
7. 9688737 - Protease stabilized acylated insulin analogues (2017-06-27),
8. 9657079 - Truncated GLP-1 derivatives and their therapeutical use (2017-05-23),
9. RE46170 - Insulin derivatives (2016-10-03),
10. RE45670 - Aryl carbonyl derivatives as therapeutic agents (2015-09-14),
11. 9040660 - Long-acting gastrin derivatives (2015-05-26),
12. 9035020 - Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids (2015-05-19),
13. 8962794 - Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids (2015-02-24),
14. 8933021 - Insulin derivative (2015-01-13),
15. 8835379 - Derivatives of CGRP (2014-09-16),

Title: Janos Tibor Kodra: Pioneering Innovations in Copenhagen

Introduction:

Janos Tibor Kodra, a visionary inventor based in Copenhagen, Denmark, has left an indelible mark on the world of technology with his passion for innovation and relentless pursuit of excellence. His 28 patents attest to his remarkable contributions to the field of protein conjugates and GLP-1 analogues, revolutionizing the treatment of metabolic disorders.

Latest Patents:

Kodra's latest patents include groundbreaking inventions such as the "Oligomer extended insulin-Fc conjugates." This innovation focuses on extending insulins with covalently attached Fc monomer polypeptides for treating metabolic disorders. Additionally, his invention of "GLP-1 derivatives and uses thereof" showcases stable compounds for treating type 2 diabetes, emphasizing the importance of maintaining receptor activation while resisting degradation.

Career Highlights:

Having worked at renowned companies like Novo Nordisk A/S, Kodra has demonstrated his expertise in the pharmaceutical industry. His innovative solutions have paved the way for advancements in healthcare, inspiring novel approaches to combatting metabolic conditions. Kodra's dedication to pushing the boundaries of science has earned him recognition as a trailblazer in his field.

Collaborations:

Throughout his career, Kodra has collaborated with esteemed professionals such as Jesper F. Lau and Peter Madsen. Together, they have spearheaded research initiatives that have led to impactful breakthroughs in pharmaceutical development. Their collective efforts have enriched the industry and fostered a culture of collaboration and innovation.

Conclusion:

Janos Tibor Kodra's unwavering commitment to innovation and transformative research serves as a beacon for aspiring inventors worldwide. His pioneering spirit continues to shape the future of technology and inspire a new generation of visionaries to push the boundaries of what is possible in the realm of metabolic disorder treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…